Published

Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Anthropology of Consciousness
Date: 2022-08-22
Source: OpenAlex
DOI: 10.1111/anoc.12154
PubMed: Unavailable

Authors

Neşe Devenot Trey Conner Richard Doyle

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction Headache / Migraine Clinical Trial Review Article Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward2026-03-01 Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative2022-08-22

Related papers

S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-ControlClinicalTrials.gov · 2026-05-04 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15